{"denoms":[{"counts":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"147"}],"units":"Participants"}],"groups":[{"description":"In Treatment Crossover Period 1 participants first received pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles, followed by pembrolizumab IV for three 21-day cycles in Treatment Crossover Period 2. After completion of the Treatment Crossover Period, participants entered the Treatment Continuation Period where they received their preferred intervention for up to 17 21-day cycles (up to \\~1 year) for RCC and melanoma, and for up to 35 21-day cycles (up to \\~2 years) for NSCLC.","id":"BG000","title":"Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV"},{"description":"In Treatment Crossover Period 1 participants first received pembrolizumab IV for three 21-day cycles, followed by pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles in Treatment Crossover Period 2. After completion of the Treatment Crossover Period, participants entered the Treatment Continuation Period where they received their preferred intervention for up to 17 21-day cycles (up to \\~1 year) for RCC and melanoma, and for up to 35 21-day cycles (up to \\~2 years) for NSCLC.","id":"BG001","title":"Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.8","value":"59.7"},{"groupId":"BG001","spread":"12.5","value":"63.2"},{"groupId":"BG002","spread":"12.3","value":"61.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"57"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"90"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"53"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"77"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"118"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}]}